Condition: Degenerative Aortic Valve Disease · Sponsor: Heart Center Leipzig - University Hospital
The overall hypothesis is that redo aortic valve replacement (rAVR) is superior to valve-invalve transcatheter aortic valve replacement (ViV-TAVR) for the composite endpoint of freedom from all-cause mortality, all-cause stroke, myocardial infarction, and rehospitalization for heart failure or aortic valve re-intervention at 5 years.
This description comes directly from the study's public registry record.
Michael Borger · 03418650 · Michael.Borger@helios-gesundheit.de
Matthias Raschpichler · matthias.raschpichler@helios-gesundheit.de
Always discuss trial participation with your own doctor first.
| Herzzentrum Leipzig GmbH | Leipzig, Saxony, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07462624